Free Trial
OTCMKTS:BIOQ

Bioqual 1/23/2024 Earnings Report

Bioqual logo
$40.00 0.00 (0.00%)
As of 10/10/2025

Bioqual EPS Results

Actual EPS
$0.54
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioqual Revenue Results

Actual Revenue
$15.87 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bioqual Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bioqual's next earnings date is estimated for Monday, October 20, 2025, based on past reporting schedules.

Conference Call Resources

Bioqual Earnings Headlines

BIOQUAL Presents Financial Results for Fiscal Year 2025
1 Hour Once A Day
My top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to help regular investors generate enough income to become financially independent… Without taking on excessive amounts of risk. I’m talking about having the opportunity to collect $500 on Monday… $563 on Wednesday… Then as much as $625 on Friday.tc pixel
See More Bioqual Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email.

About Bioqual

Bioqual (OTCMKTS:BIOQ), Inc. is a U.S.-based contract research organization specializing in preclinical immunology and pharmacology services for the biopharmaceutical industry. The company offers a range of in vivo and in vitro testing solutions designed to support vaccine development, immuno-oncology programs and other therapeutic modalities. Bioqual’s service portfolio encompasses assay development, safety and efficacy studies, biomarker analysis and specialized immunogenicity assessments.

Leveraging proprietary humanized animal models and nonhuman primate research platforms, Bioqual helps clients evaluate biological activity, toxicity and pharmacokinetics of investigational compounds. The company’s facilities include vivarium capabilities, tissue culture laboratories and bioanalytical suites configured to meet regulatory standards. Bioqual’s scientific team collaborates with pharmaceutical and biotechnology companies to design study protocols, collect and analyze data, and prepare comprehensive study reports for regulatory submissions.

Headquartered in Maryland with additional facilities in California, Bioqual serves a global client base ranging from emerging biotech firms to large pharmaceutical corporations. Its geographically distributed laboratories enable scalable study execution and logistical flexibility. While detailed leadership information is not broadly disclosed, Bioqual’s management is led by seasoned professionals with extensive experience in preclinical development and immunology research.

View Bioqual Profile

More Earnings Resources from MarketBeat